Kalfeist L, Ledys F, Petit S, Poirrier C, et al. Co-targeting TGF-beta and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet. J Clin Invest 2025;135:e184422.
PMID: 40590231